These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
296 related articles for article (PubMed ID: 34117981)
1. Cardiooncology-dealing with modern drug treatment, long-term complications, and cancer survivorship. de Wall C; Bauersachs J; Berliner D Clin Exp Metastasis; 2021 Aug; 38(4):361-371. PubMed ID: 34117981 [TBL] [Abstract][Full Text] [Related]
2. [Tumor effects on the heart and circulation]. Anker MS; Hadzibegovic S; von Haehling S Internist (Berl); 2020 Nov; 61(11):1120-1124. PubMed ID: 33052455 [TBL] [Abstract][Full Text] [Related]
3. Cardiotoxic effects of chemotherapy: A review of both cytotoxic and molecular targeted oncology therapies and their effect on the cardiovascular system. Babiker HM; McBride A; Newton M; Boehmer LM; Drucker AG; Gowan M; Cassagnol M; Camenisch TD; Anwer F; Hollands JM Crit Rev Oncol Hematol; 2018 Jun; 126():186-200. PubMed ID: 29759560 [TBL] [Abstract][Full Text] [Related]
4. Cardio-Oncology: An Update on Cardiotoxicity of Cancer-Related Treatment. Lenneman CG; Sawyer DB Circ Res; 2016 Mar; 118(6):1008-20. PubMed ID: 26987914 [TBL] [Abstract][Full Text] [Related]
5. Management and research in cancer treatment-related cardiovascular toxicity: Challenges and perspectives. Cautela J; Lalevée N; Ammar C; Ederhy S; Peyrol M; Debourdeau P; Serin D; Le Dolley Y; Michel N; Orabona M; Barraud J; Laine M; Bonello L; Paganelli F; Barlési F; Thuny F Int J Cardiol; 2016 Dec; 224():366-375. PubMed ID: 27673693 [TBL] [Abstract][Full Text] [Related]
6. Cardio-oncology in Austria: cardiotoxicity and surveillance of anti-cancer therapies : Position paper of the Heart Failure Working Group of the Austrian Society of Cardiology. Bergler-Klein J; Rainer PP; Wallner M; Zaruba MM; Dörler J; Böhmer A; Buchacher T; Frey M; Adlbrecht C; Bartsch R; Gyöngyösi M; Fürst UM Wien Klin Wochenschr; 2022 Sep; 134(17-18):654-674. PubMed ID: 35507087 [TBL] [Abstract][Full Text] [Related]
8. Cardio-oncology - strategies for management of cancer-therapy related cardiovascular disease. Totzeck M; Schuler M; Stuschke M; Heusch G; Rassaf T Int J Cardiol; 2019 Apr; 280():163-175. PubMed ID: 30661849 [TBL] [Abstract][Full Text] [Related]
9. Long-term cardiovascular health in adult cancer survivors. Naaktgeboren WR; Linschoten M; de Graeff A; V Rhenen A; Cramer MJ; Asselbergs FW; Maas AHEM; Teske AJ Maturitas; 2017 Nov; 105():37-45. PubMed ID: 28583397 [TBL] [Abstract][Full Text] [Related]
10. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. Pudil R; Mueller C; Čelutkienė J; Henriksen PA; Lenihan D; Dent S; Barac A; Stanway S; Moslehi J; Suter TM; Ky B; Štěrba M; Cardinale D; Cohen-Solal A; Tocchetti CG; Farmakis D; Bergler-Klein J; Anker MS; Von Haehling S; Belenkov Y; Iakobishvili Z; Maack C; Ciardiello F; Ruschitzka F; Coats AJS; Seferovic P; Lainscak M; Piepoli MF; Chioncel O; Bax J; Hulot JS; Skouri H; Hägler-Laube ES; Asteggiano R; Fernandez TL; de Boer RA; Lyon AR Eur J Heart Fail; 2020 Nov; 22(11):1966-1983. PubMed ID: 33006257 [TBL] [Abstract][Full Text] [Related]
11. Cardiotoxicity of Biological Therapies in Cancer Patients: An In-depth Review. Madanat L; Gupta R; Weber P; Kumar N; Chandra R; Ahaneku H; Bansal Y; Anderson J; Bilolikar A; Jaiyesimi I Curr Cardiol Rev; 2023; 19(3):e310522205428. PubMed ID: 35642110 [TBL] [Abstract][Full Text] [Related]
12. Challenges and solutions in management of cardiotoxicity induced by checkpoint inhibitors. Mladosievičová B; Országhová Z; Jablonická M; Rečková M; Chovanec M; Mego M Klin Onkol; 2020; 33(5):350-355. PubMed ID: 33108879 [TBL] [Abstract][Full Text] [Related]
13. The Growing Impact of Cardiovascular Oncology: Epidemiology and Pathophysiology. Tufano A; Coppola A; Galderisi M Semin Thromb Hemost; 2021 Nov; 47(8):899-906. PubMed ID: 34255338 [TBL] [Abstract][Full Text] [Related]
14. [Biomarkers in cardio-oncology patients]. Totzeck M; Glas M; Rassaf T Internist (Berl); 2020 Nov; 61(11):1114-1119. PubMed ID: 33025124 [TBL] [Abstract][Full Text] [Related]
16. Cardio-oncology Part I: chemotherapy and cardiovascular toxicity. O'Hare M; Sharma A; Murphy K; Mookadam F; Lee H Expert Rev Cardiovasc Ther; 2015 May; 13(5):511-8. PubMed ID: 25843285 [TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint inhibitors - the revolutionary cancer immunotherapy comes with a cardiotoxic price. Achim A; Liblik K; Gevaert S Trends Cardiovasc Med; 2024 Feb; 34(2):71-77. PubMed ID: 36152788 [TBL] [Abstract][Full Text] [Related]
18. What Does a Cardio-oncology Service Offer to the Oncologist and the Haematologist? Andres MS; Pan J; Lyon AR Clin Oncol (R Coll Radiol); 2021 Aug; 33(8):483-493. PubMed ID: 33832839 [TBL] [Abstract][Full Text] [Related]
19. The Role of Cardiovascular Magnetic Resonance for Surveillance of Cardiac Performance upon Receipt of Potentially Cardiotoxic Cancer Therapeutics. Parashar A; Hundley WG Curr Cardiol Rep; 2018 Oct; 20(12):142. PubMed ID: 30367282 [TBL] [Abstract][Full Text] [Related]
20. Cardiotoxicity of cancer chemotherapy: implications for children. Simbre VC; Duffy SA; Dadlani GH; Miller TL; Lipshultz SE Paediatr Drugs; 2005; 7(3):187-202. PubMed ID: 15977964 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]